Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 17/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 17/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 13/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249083 | 0.99 | KCNJ6 (0.47) | KCNJ6KCNJ3KCNJ5LMNAIRAK4 | |
| SCHEMBL3975958 | 0.86 | KCNJ6 (0.46) | KCNJ6KCNJ3KCNJ5LMNAIRAK4 | |
| SCHEMBL3860022 | 0.85 | KCNJ6 (0.46) | KCNJ6KCNJ3KCNJ5LMNAIRAK4 | |
| SCHEMBL3975969 | 0.83 | LMNA (0.44) | KCNJ6KCNJ3KCNJ5LMNA | |
| SCHEMBL3975494 | 0.83 | KCNJ6 (0.46) | KCNJ6KCNJ3KCNJ5LMNAIRAK4 | |
| SCHEMBL5011981 | 0.82 | KCNJ6 (0.48) | KCNJ6KCNJ3KCNJ5LMNAIRAK4 | |
| SCHEMBL3979959 | 0.81 | KCNJ6 (0.46) | KCNJ6KCNJ3KCNJ5LMNACRACR2A | |
| SCHEMBL3975999 | 0.81 | ADORA1 (0.47) | LMNA | |
| SCHEMBL5005238 | 0.81 | KCNJ6 (0.49) | KCNJ6KCNJ3KCNJ5LMNACRACR2A | |
| SCHEMBL3982464 | 0.81 | MAPK14 (0.59) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | GPR119, GOT2, IAPP | KCNJ6 1859/4885KCNJ3 1054/4885KCNJ5 1245/4885 |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | GPR119, GOT2, IAPP | KCNJ6 1859/4885KCNJ3 1054/4885KCNJ5 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.